期刊
BRITISH JOURNAL OF CANCER
卷 112, 期 9, 页码 1421-1427出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2015.124
关键词
-
类别
资金
- NIH [P01 CA168585, P01 CA132681, P50 CA086306, R01 CA199205]
- Dr Robert Vigen memorial fund
- Ressler Family Foundation
- Louise Belley and Richard Schnarr Fund
- Wesley Coyle Memorial Fund
- Garcia-Corsini Family Fund
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types. Anti-PD-1 and anti-PD-L1 antibodies have resulted in long-term responses with minimal side effects in significant numbers of patients with melanoma, lung, kidney, bladder and triple-negative breast cancer, as well as in chemotherapy-refractory Hodgkin disease. There is already evidence from at least one randomised trial that anti-PD-1 therapy is superior to chemotherapy in the treatment of patients with metastatic melanoma, and two anti-PD-1 antibodies, pembrolizumab and nivolumab, have been approved by the US Food and Drug Administration for the treatment of patients previously treated for metastatic melanoma. It is anticipated that approvals by drug regulatory bodies will be forthcoming in several cancers in the next months.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据